Company Snapshot: KemPharm, Inc.
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.
- Oct 27 2021 AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress
- Oct 20 2021 KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)
- Oct 19 2021 KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
- Sep 27 2021 KemPharm to Present at the Benzinga Healthcare Small Cap Conference